High-sensitivity troponin levels positively correlated with late gadolinium enhancement (OR 32.81; 95% CI 3.56-302.59; P=0.002), serving as a biomarker for staging Fabry cardiomyopathy.
Observational (n=75)
Does high-sensitivity troponin (hs-TNT) measurement correlate with myocardial fibrosis and predict cardiomyopathy progression in patients with Fabry disease?
High-sensitivity troponin is an accurate biomarker for detecting replacement fibrosis and predicting cardiomyopathy progression in patients with Fabry disease.
Effect estimate: OR 32.81 (95% CI 3.56-302.59)
p-value: p=0.002
BACKGROUND: High-sensitivity troponin (hs-TNT), a biomarker of myocardial damage, might be useful for assessing fibrosis in Fabry cardiomyopathy. We performed a prospective analysis of hs-TNT as a biomarker for myocardial changes in Fabry patients and a retrospective longitudinal follow-up study to assess longitudinal hs-TNT changes relative to fibrosis and cardiomyopathy progression. METHODS AND RESULTS: For the prospective analysis, hs-TNT from 75 consecutive patients with genetically confirmed Fabry disease was analyzed relative to typical Fabry-associated echocardiographic findings and total myocardial fibrosis as measured by late gadolinium enhancement (LE) on magnetic resonance imaging. Longitudinal data (3.9±2.0 years), including hs-TNT, LE, and echocardiographic findings from 58 Fabry patients, were retrospectively collected. Hs-TNT level positively correlated with LE (linear correlation coefficient, 0.72; odds ratio, 32.81 95% CI, 3.56-302.59; P=0.002); patients with elevated baseline hs-TNT (>14 ng/L) showed significantly increased LE (median: baseline, 1.9 1.1-3.3 %; follow-up, 3.2 2.3-4.9 %; P<0.001) and slightly elevated hs-TNT (baseline, 44.7 30.1-65.3 ng/L; follow-up, 49.1 27.6-69.5 ng/L; P=0.116) during follow-up. Left ventricular wall thickness and EF of patients with elevated hs-TNT were decreased during follow-up, indicating potential cardiomyopathy progression. CONCLUSIONS: hs-TNT is an accurate, easily accessible clinical blood biomarker for detecting replacement fibrosis in patients with Fabry disease and a qualified predictor of cardiomyopathy progression. Thus, hs-TNT could be helpful for staging and follow-up of Fabry patients.
Seydelmann et al. (2016) conducted an observational in Fabry disease (n=75). High-sensitivity troponin (hs-TNT) was evaluated on Correlation of hs-TNT with late gadolinium enhancement (LE) (OR 32.81, 95% CI 3.56-302.59, p=0.002). High-sensitivity troponin levels positively correlated with late gadolinium enhancement (OR 32.81; 95% CI 3.56-302.59; P=0.002), serving as a biomarker for staging Fabry cardiomyopathy.